ERIVEDGE 150 MG — DIN 02409267
VISMODEGIB : 150 MG · HOFFMANN-LA ROCHE LIMITED · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is ERIVEDGE?
ERIVEDGE 150 MG contains VISMODEGIB : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02409267, held by HOFFMANN-LA ROCHE LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Aug-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ERIVEDGE used for?
ERIVEDGE (vismodegib) is indicated for the treatment of adult patients with histologically confirmed metastatic basal cell carcinoma (BCC) or locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy. The indication is granted market authorization based on objective response rate (ORR) demonstrated in a single-arm Phase II trial. Overall survival (OS) benefit in a single-arm trial cannot be confirmed. In the pivotal trial, the majority of the clinical responses occurred within 16 weeks. Benefit of continued treatment should be regularly assessed, with the optimal duration of therapy varying for each individual patient.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Vismodegib cost around the world?
Vismodegib is listed on 9 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Norway | max AUP (pharmacy retail) | 1 | 3 | NOK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 1 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
11 pack listings across 9 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Vismodegib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | ERIVEDGE is supplied in high density polyethylene (HDPE) bottles (28 capsules per bottle). |
| Storage | Store at room temperature (15 - 30 °C). Store in the original package. Keep the bottle tightly closed in order to protect from moisture and heat. Keep out of sight and reach of children. This medicine should not be used after the expiry date (EXP) shown on the pack. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Vismodegib |
|---|---|
| ATC code | L01XJ01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02409267 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2409267 |
| Brand name | ERIVEDGE |
| Generic / active ingredient | VISMODEGIB : 150 MG |
| Market authorization holder | HOFFMANN-LA ROCHE LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L01XJ01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XJ |
| Current status | MARKETED |
| Status date | 09-Aug-2013 |
| Original market date | 2013-08-09 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
The recommended dose of ERIVEDGE is 150 mg once daily. ERIVEDGE should be continued until disease progression or until unacceptable toxicity. Because ERIVEDGE is only available as a single 150 mg capsule, dose adjustments are managed by therapy interruptions. ERIVEDGE can be taken without regard to meals. Capsules must be swallowed whole and must not be opened or crushed under any circumstances. If a planned dose of ERIVEDGE is missed, patients should not take the missed dose but resume dosing with the next scheduled dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
ERIVEDGE (vismodegib) is contraindicated in: • Female patients who are pregnant and females at risk of becoming pregnant. • Breastfeeding female patients. • Female patients of childbearing potential (FCBP) who do not comply with the ERIVEDGE Pregnancy Prevention Program. • Male patients who do not comply with the contraceptive measures of the ERIVEDGE Pregnancy Prevention Program. • Children and adolescents aged below 18 years. • Patients who are hypersensitive to vismodegib or to any ingredient in the formulation.
Warnings and precautions
ERIVEDGE should be initiated and monitored only under the supervision of a physician qualified in the use of cancer therapies and with a full understanding of the risks of ERIVEDGE therapy and monitoring requirements. ERIVEDGE can cause embryo-fetal death or severe birth defects. ERIVEDGE has not been studied in patients with severe renal impairment. ERIVEDGE is not recommended for use in patients with severe hepatic impairment since limited data are available. ERIVEDGE is available only through a controlled distribution program called the ERIVEDGE Pregnancy Prevention Program (EPPP). ERIVEDGE can cause irreversible premature fusion of the epiphyses in pediatric patients. ERIVEDGE can cause severe cutaneous adverse reactions including Toxic Epidermal Necrolysis (TEN) and Stevens Johnson Syndrome (SJS). Patients experiencing a severe cutaneous adverse reaction should discontinue treatment with ERIVEDGE and seek prompt medical evaluation. ERIVEDGE has been shown to cause severe irreversible changes in the male reproductive systems, growing teeth, and closure of the epiphyseal growth plate in animal species, indicating potential risks for short stature, tooth deformities, and future reproductive problems in infants and children. Patients must not donate blood or blood products while on treatment and for 24 months after treatment discontinuation. Patients with advanced BCC have an increased risk of developing cutaneous squamous cell carcinoma (cuSCC). All patients should be monitored routinely while taking ERIVEDGE. Cardiac-related adverse events such as atrial fibrillation, cardiac flutter, cardiac failure, restrictive cardiomyopathy, angina, myocardial infarction, and left ventricular dysfunction have been observed. Fatal cases of acute myocardial infarction and ischemic stroke were reported. Grade ≥ 3 cardiac adverse events typically occurred in patients with a significant prior history of cardiac disease. Vascular-related disorders include Grade ≥ 3 hypertension and orthostatic hypotension. Thromboembolic events such as thrombosis, deep vein thrombosis, and pulmonary embolism (including a fatal case) have been reported. Hepatotoxicity occurred in patients treated with ERIVEDGE. Serious cases of hepatotoxicity, including cholestasis, hepatitis and hepatocellular injury, have been observed. Pre-existing liver disease, underlying malignancy, concomitant hepatotoxic medications and systemic infections may be risk factors. Renal disorders and cases of renal failure, including a fatal case, have been observed.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L01XJ
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Glasdegib | DAURISMO | 2 | 2 | Yes |
| Sonidegib | ODOMZO | 1 | 1 | Yes |
| Vismodegib | ERIVEDGE | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · Asparaginase · Belzutifan · Eribulin · Estramustine · Hydroxycarbamide · Lurbinectedin · Mitotane · Pegaspargase · Pentostatin · Selinexor · Sotorasib · Tebentafusp · Venetoclax | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XA | Carboplatin · Cisplatin · Oxaliplatin | 45 | 12 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · Lisocabtagene Maraleucel · Tisagenlecleucel | 8 | 5 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XH | Romidepsin · Vorinostat | 2 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ERIVEDGE called?
Also recorded in Canada as: vismodegib 150 MG Oral Capsule [Erivedge] (US), vismodegib 150 MG Oral Capsule (US), VISMODEGIB (US), VISMODEGIB (GLOBAL), VISMODEGIB (UK).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.